Gemcitabine for Recurrent Ovarian Cancer

Links shared publicly online about this topic

Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR

empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on June 5, 2011 at 6:53 pm By:

eMPR MPR Medical Publisher

#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq

12 months ago...

Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA

oncologynurseadvisor.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on June 5, 2011 at 6:30 pm By:

ONAcom OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher

Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7

12 months ago...

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

buzzup.com — “Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.View full resource at buzzup.com

  • View Related
  • Share

Most Recently Shared on March 18, 2010 at 12:25 pm By:

Ovarian_Cancer_ News-Medical.Net Health News

Ovarian Cancer News: Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Stu... http://buzzup.com/qrlm_

2 years ago...

First Recurrent Gene Fusion Identified In Ovarian Cancer

medicalnewstoday.com — “Researchers studying ovarian cancer have discovered that, in a substantial fraction of ovarian tumors, a gene closely related to the estrogen receptor is broken and fused to an adjacent gene by aView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on September 22, 2011 at 7:05 am By:

mnt_ovariancanc MNT Ovarian Cancer Health News

First Recurrent Gene Fusion Identified In Ovarian Cancer http://mnt.to/3ZMY #ovariancancer

8 months ago...

Ovarian cancer vaccine: Can it prevent recurrence? - MayoClinic.com

mayoclinic.com — “Research continues to evaluate the role of an ovarian cancer vaccine to prevent recurrence.View full resource at mayoclinic.com

  • View Related
  • Share

Most Recently Shared on March 24, 2012 at 2:20 am By:

J_Bohlen Julie Bohlen Health Executive and Active Health Library

Ovarian cancer vaccine: Can it prevent recurrence?: Research continues to evaluate the role of an ovarian cancer... http://t.co/fbwU0zDZ

2 months ago...

Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer

medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.View full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on December 9, 2011 at 9:07 am By:

mnt_ovariancanc MNT Ovarian Cancer Health News

Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer

6 months ago...

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer " JCO

jco.ascopubs.org — “Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer " JCOView full resource at jco.ascopubs.org

  • View Related
  • Share

Most Recently Shared on September 17, 2010 at 11:38 am By:

OvarianCancer_ Ovarian Cancer OW OW Health

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial O... http://bit.ly/b728h5

2 years ago...

Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer

onclive.com — “Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.View full resource at onclive.com

  • View Related
  • Share

Most Recently Shared on July 27, 2011 at 7:45 pm By:

ONClive Editor Oncology

Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer http://t.co/gLOIrDB

10 months ago...

Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability - ONA

oncologynurseadvisor.com — “The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on June 5, 2011 at 5:23 pm By:

ONAcom OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher

Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability http://goo.gl/fb/ldXlW

12 months ago...

Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - ONA

oncologynurseadvisor.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.View full resource at oncologynurseadvisor.com

  • View Related
  • Share

Most Recently Shared on June 7, 2010 at 8:20 pm By:

Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer

onclive.com — “Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian CancerView full resource at onclive.com

  • View Related
  • Share

Most Recently Shared on May 5, 2011 at 6:51 pm By:

ONClive Editor Oncology

OncLive TV: Dr. Beth Karlan from @CedarsSinai Discusses AMG 386 in Recurrent Ovarian Cancer http://goo.gl/eO2xa

1 year ago...

Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer - MPR

empr.com — “Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on June 7, 2010 at 8:14 pm By:

eMPR MPR Medical Publisher

MPR News: Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer: Amgen announced that AMG 386, combin... http://bit.ly/cBbIUj

2 years ago...

Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer : Internal Medicine News

internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice treView full resource at internalmedicinenews.com

  • View Related
  • Share

Most Recently Shared on June 5, 2011 at 11:58 pm By:

MiriamETucker Miriam E. Tucker Patient Expert

RT @IntMedNews: Bevacizumab Halves Progression Risk in Recurrent Ovarian #Cancer http://bit.ly/ipBNsP

12 months ago...

Detecting breast cancer recurrence

physorg.com — “Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain and ovarian cancer before succumbing to the disease in their early ...View full resource at physorg.com

  • View Related
  • Share

Most Recently Shared on October 20, 2010 at 3:12 pm By:

Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer

hindawi.com — “Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian CancerView full resource at hindawi.com

  • View Related
  • Share

Most Recently Shared on August 29, 2011 at 6:40 pm By:

OvarianCancer_ Ovarian Cancer OW OW Health

Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer: Thi... http://t.co/C0fygZk

9 months ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

  • eMPR

    MPR

    eMPR.com provides up-to-date, concise drug information at the point-of-care.

    View Profile

  • ONAcom

    OncologyNurseAdvisor

    Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.

    View Profile

  • Ovarian_Cancer_

    News-Medical.Net

    Stay up to date with the latest Ovarian Cancer news and research via News-Medical.Net

    View Profile

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390